Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Multicenter Study to Assess the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of KPG-818 in Patients With Systemic Lupus Erythematosus

NCT04643067 is registered in ClinicalTrials.gov with Kangpu Biopharmaceuticals, Ltd. as lead sponsor.

NCT NCT04643067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04643067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Multicenter Study to Assess the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of KPG-818 in Patients With Systemic Lupus Erythematosus
Lead sponsor
Kangpu Biopharmaceuticals, Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
June 3, 2021
Completion date
June 29, 2023
Enrollment
64 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

sle; drug